First human test of novel brain cancer vaccine shows promise

NCT ID NCT04116658

Completed Disease control Sponsor: Enterome Source: ClinicalTrials.gov ↗

Summary

This study tested a new type of cancer vaccine called EO2401 in adults whose aggressive brain tumor (glioblastoma) had returned after standard treatment. The main goals were to check the vaccine's safety and see if it could trigger an immune response against the cancer. The vaccine was tested alone and in combination with other immunotherapy drugs.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Centre Georges François Leclerc

Dijon, 21000, France
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Hôpital Pitié-Salpétrière

Paris, 75013, France
Institit Catala D'Oncologia - Hospital Duran i Reynals

L'Hospitalet de Llobregat, 8908, Spain
Klinik und Poliklinik für Neurologie Universitätsklinikum Bonn

Bonn, 53105, Germany
Medizinische Fakultät Mannheim der Universität Heidelberg

Mannheim, 68167, Germany
Neurologische Klinik & Nationales Zentrum für Tumorenerkrankungen Heidelberg Universitätsklinikum Heidelberg

Heidelberg, 69120, Germany
Universitätsklinikum Frankfurt Goethe-Universität Dr. Senckenbergisches Institut für Neuroonkologie

Frankfurt am Main, 60528, Germany
Zentrum für Neuroonkologie Universitätsklinikum Tübingen

Tübingen, 72076, Germany

Conditions

Explore the condition pages connected to this study.

GLIOBLASTOMA, ADULT